Investors Alert: Corcept Therapeutics Faces Lawsuit Over Regulatory Non-Compliance and Stock Plummet

Investors on Notice: Class Action Against Corcept Therapeutics

Hagens Berman, a prominent shareholder rights law firm, has announced a securities class action lawsuit against Corcept Therapeutics Inc. (NASDAQ: CORT), urging investors affected by the stock's dramatic decline to take action. The lawsuit, filed in the Northern District of California under the title Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, pertains to holders of CORT common stock from October 31, 2024, to December 30, 2025.

Background of the Allegations

The primary allegations against Corcept revolve around claims that the company misrepresented the regulatory status of its key drug candidate, relacorilant. While Corcept promoted this drug with assertions of strong supporting evidence and imminent approval, it appears that the FDA had consistently raised concerns about the adequacy of the clinical data. Reports suggest that the FDA warned Corcept on several occasions during preliminary meetings that the clinical evidence was insufficient to support an approval application.—a critical fact that was allegedly kept from investors.

The litigation seeks to rectify the losses incurred by investors who believed in Corcept's assurances of success without being privy to crucial regulatory warnings.

Stock Market Impact

The situation came to a head on December 31, 2025, when Corcept disclosed that it had received a Complete Response Letter (CRL) from the FDA. This announcement led to a staggering drop in the stock price from $70.20 to $34.80 in one day, obliterating over $3.6 billion in market capitalization.

In the aftermath, a redacted CRL revealed that the FDA found it impossible to arrive at a favorable benefit-risk analysis without further evidence of the drug's effectiveness. This dramatic turn of events has raised eyebrows and spurred legal scrutiny as the market ponders what went wrong.

As indicated by Reed Kathrein, a partner at Hagens Berman, the litigation aims to expose the alleged disparity between Corcept's optimistic narrative and the FDA's private warnings. Kathrein stressed that the lawsuit asserts that the company knowingly proceeded with the submission despite understanding the potential adversities, misleading investors in the process.

Key Dates and Investors Rights

For those who purchased Corcept stock within the specified class period, an important deadline looms. Investors have until April 21, 2026, to formally become involved in the lawsuit as lead plaintiff. Those who have experienced significant financial loss or have pertinent information regarding the investigation are encouraged to take action now.

Hagens Berman has made it easy for interested investors to get involved or simply to learn more. They can visit the firm's CORT Case Page for more information, download a copy of the complaint, and familiarize themselves with the lead plaintiff application process.

In light of these developments, individuals holding Corcept stocks are strongly urged to evaluate their options carefully, as the potential consequences could be significant. Whistleblowers with non-public information about Corcept’s implications may also consider stepping forward to assist the investigation, as the SEC has introduced a whistleblower program offering rewards of up to 30% of any successful recovery.

About Hagens Berman

Hagens Berman is a global complex litigation firm dedicated to championing the rights of investors and numerous stakeholders harmed by corporate failures and negligence. The firm has a robust track record, having recovered upwards of $2.9 billion in this sector, reinforcing the vital role they play in safeguarding investors' rights and promoting corporate accountability. For further updates and information, follow them on their social media platforms where they regularly share insights and announcements.

In conclusion, the situation around Corcept Therapeutics serves as a stark reminder of the critical importance of transparent communication between companies and their investors. The ongoing lawsuit emphasizes the necessity for diligence and vigilance in the investment landscape as stakeholders seek both legal redress and accountability.